List of Excipients in Branded Drug DESIPRAMINE HYDROCHLORIDE

Generic Drugs Containing DESIPRAMINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Sandoz Inc	desipramine hydrochloride	0781-8218	CELLULOSE, MICROCRYSTALLINE
Sandoz Inc	desipramine hydrochloride	0781-8218	HYDROXYPROPYL CELLULOSE
Sandoz Inc	desipramine hydrochloride	0781-8218	HYPROMELLOSE 2910
Sandoz Inc	desipramine hydrochloride	0781-8218	LACTOSE MONOHYDRATE
Sandoz Inc	desipramine hydrochloride	0781-8218	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in DESIPRAMINE HYDROCHLORIDE?

# Of NDCs	Excipient
1	ANHYDROUS LACTOSE
18	CELLULOSE, MICROCRYSTALLINE
2	CITRIC ACID MONOHYDRATE
9	CROSCARMELLOSE SODIUM
4	FD&C BLUE NO. 1

Desipramine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: September 5, 2026

Desipramine hydrochloride is a legacy tricyclic antidepressant with limited patent protection and a narrow commercial base. The strongest commercial opportunities are not new-molecule exclusivity plays. They are low-cost, reliable generic manufacturing; differentiated oral liquids or dispersible dosage forms; excipient-controlled products for lactose-sensitive or dysphagia patients; and supply contracts for psychiatric, hospital, and specialty-pharmacy channels.

What is the regulatory and commercial status of desipramine hydrochloride?

Desipramine hydrochloride is the hydrochloride salt of desipramine, a secondary-amine tricyclic antidepressant marketed historically as Norpramin. Current commercial products are generally immediate-release oral tablets supplied through generic manufacturers. FDA-approved strengths have historically included 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg tablets.[1][2]

Attribute	Desipramine hydrochloride
Therapeutic class	Tricyclic antidepressant
Dosage form	Immediate-release oral tablet
Common strengths	10, 25, 50, 75, 100, 150 mg
Regulatory pathway	Abbreviated New Drug Application, where an approved reference product is available
Reference brand	Norpramin
Primary commercial market	Generic prescription market
Biologic or biosimilar status	Not applicable
Main technical challenge	Dose uniformity, tablet robustness, supply continuity
Main commercial constraint	Small and declining antidepressant market relative to SSRIs and SNRIs

Desipramine has a narrow role in current prescribing because clinicians generally favor newer antidepressants with broader guideline support and more favorable safety profiles. Demand persists in selected patients, including treatment-resistant cases, patients who previously responded to the drug, and certain off-label uses such as neuropathic pain or attention-related disorders.

The product’s commercial value is therefore driven by availability and dependable quality rather than brand-level differentiation.

What excipients are used in desipramine hydrochloride tablets?

Excipients vary by manufacturer, strength, compression platform, and market. Public FDA labeling and DailyMed records for desipramine hydrochloride tablets identify conventional solid-dose excipients such as lactose or other diluents, starch, povidone or related binders, and magnesium stearate.[2][3]

Typical excipient functions include:

Excipient category	Representative materials	Function
Diluent	Lactose monohydrate, microcrystalline cellulose, dibasic calcium phosphate	Provides tablet mass and improves compression
Disintegrant	Corn starch, sodium starch glycolate, crospovidone	Promotes tablet breakup after administration
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Lubricant	Magnesium stearate, stearic acid, sodium stearyl fumarate	Reduces sticking and ejection force
Glidant	Colloidal silicon dioxide	Improves powder flow
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Protects the tablet and supports identification
Colorant	Iron oxides or approved synthetic colors	Differentiates strengths
Printing ink	Pharmaceutical-grade pigments and solvents	Product identification

The exact formulation must be verified against the current manufacturer’s package insert and inactive-ingredient declaration. Excipients can differ between strengths and between approved products.

Desipramine hydrochloride is a low-dose active pharmaceutical ingredient in several strengths. The 10 mg and 25 mg tablets create a greater formulation burden than the 100 mg and 150 mg tablets because the active represents a smaller percentage of total tablet weight. Blend uniformity, segregation control, and sampling strategy become important commercial-quality variables.

Which excipient platform is most suitable for desipramine hydrochloride?

A conventional immediate-release direct-compression or dry-granulation platform is generally the most commercially rational approach. A wet-granulation process can improve content uniformity and flow but adds processing cost, moisture exposure, and validation requirements.

Lactose-based formulation

Lactose is a practical filler for desipramine tablets because it is widely available, inexpensive, and compatible with standard tablet manufacturing. Its disadvantages are lactose intolerance concerns, potential supplier variability, and the need to manage the risk of Maillard-type interactions with amine-containing drugs under certain conditions.

A lactose-based product is suitable for a cost-focused generic when:

• The formulation has acceptable impurity and stability performance.
• The target market does not require lactose-free positioning.
• The manufacturer has reliable pharmaceutical-grade lactose supply.
• The tablets meet dissolution and content-uniformity requirements across all strengths.

Microcrystalline-cellulose formulation

Microcrystalline cellulose can support direct compression and provide stronger tablets at relatively low compression force. It is attractive for a lactose-free product and may reduce dependence on wet granulation.

Potential limitations include:

• Higher tablet weight at equivalent performance.
• Greater sensitivity to lubricant level and blending time.
• Possible differences in disintegration and dissolution between grades.
• Higher cost than commodity lactose in some supply markets.

A microcrystalline-cellulose platform is most useful when the sponsor wants a lactose-free claim, a simplified manufacturing process, or a product designed for contract manufacturing across multiple strengths.

Starch-based formulation

Starch can function as both a diluent and disintegrant. It is familiar to generic manufacturers and supports immediate-release performance. Starch-based systems can require tighter moisture control, especially when the active or finished product has stability sensitivity.

Coprocessed excipients

Coprocessed excipients can improve flow, compressibility, and tablet robustness. They may help a manufacturer produce small, low-dose tablets with lower defect rates. Their commercial benefit must exceed the cost of qualifying a new supplier and demonstrating formulation equivalence.

For an established generic tablet, coprocessed excipients are more likely to be operational tools than sources of durable exclusivity.

What excipient strategies create commercial differentiation?

The strongest differentiation opportunities are patient- and supply-chain-focused rather than patent-focused.

Lactose-free tablets

A lactose-free formulation can address pharmacy substitution, patient preference, and institutional formulary requirements. The claim must be supported by the complete composition, including coating and printing components.

This is a modest opportunity because lactose intolerance does not automatically prevent use of a lactose-containing tablet, and many patients do not require a lactose-free antidepressant. The opportunity becomes more credible in a product line positioned around broad excipient avoidance.

Dye-free tablets

A dye-free product can appeal to patients with colorant sensitivities and to institutional buyers seeking simplified formulations. The manufacturer must preserve strength differentiation through shape, debossing, packaging, or other permitted identification methods.

The commercial advantage is limited unless paired with a broader clean-label or excipient-minimization strategy.

Gluten-free and allergen-controlled supply

Pharmaceutical tablets generally do not contain gluten-derived excipients, but manufacturers must control raw-material sourcing and cross-contamination. A documented gluten-free or allergen-control position may assist hospital and specialty-pharmacy procurement.

Such positioning should be supported by supplier qualification, analytical controls, and a defensible quality statement rather than broad consumer marketing.

Small, swallowable tablets

Desipramine is used in older adults and patients taking multiple medications. Smaller tablets with adequate mechanical strength can improve acceptability. The 10 mg and 25 mg strengths are particularly suitable for tablet-size optimization.

The main technical risk is that reducing tablet mass can worsen content uniformity and friability. A high-functionality filler or dry-granulation platform may help.

Unit-dose packaging

Blister packaging, calendar packs, and unit-dose bottles can support adherence and institutional dispensing. Packaging differentiation may be more commercially valuable than a novel excipient because the product’s prescribing volume is concentrated in chronic use and specialty dispensing.

Child-resistant packaging remains necessary where applicable, while unit-dose formats must preserve moisture and light stability.

What formulations are protected by patents?

No meaningful active-molecule patent barrier is expected for desipramine hydrochloride. Desipramine was developed decades ago, and the core compound, hydrochloride salt, and conventional immediate-release tablet technology are outside ordinary new-drug patent life.

The relevant intellectual-property categories are:

IP category	Commercial relevance
Desipramine compound patent	Expired
Hydrochloride salt patent	Expected to be expired or commercially irrelevant
Conventional immediate-release tablet	Generally not a durable barrier
Specific excipient composition	Possible only if unusually novel and still enforceable
Oral liquid formulation	Potential 505(b)(2) or formulation patent opportunity
Modified-release dosage form	Potential formulation and method-of-use opportunity
Taste-masking system	Possible composition or process protection
Manufacturing process	Possible trade-secret value; limited blocking power
Packaging and adherence system	Possible design or utility protection

An excipient formulation could receive patent protection only if it satisfies novelty, non-obviousness, written-description, enablement, and other applicable requirements. Simply replacing lactose with microcrystalline cellulose would rarely support a strong, durable patent position.

When does desipramine hydrochloride lose exclusivity?

Desipramine hydrochloride lost meaningful market exclusivity decades ago. The relevant commercial question is not the expiration of the original product patent. It is whether a current generic sponsor has any product-specific exclusivity, listed patent, or regulatory exclusivity associated with a new dosage form.

For a conventional tablet:

• New chemical entity exclusivity is unavailable.
• Orphan-drug exclusivity is not associated with the standard product.
• Pediatric exclusivity is not expected to create a material barrier.
• Patent-term extension is not commercially relevant to the legacy product.
• Generic entry depends primarily on FDA approval, manufacturing capacity, and market economics.

The FDA Orange Book should be checked for the current reference-listed drug, listed patents, and therapeutic-equivalence codes.[1] For legacy products, the practical barrier is usually product availability rather than enforceable patent rights.

What is the Orange Book status of desipramine hydrochloride?

The Orange Book identifies FDA-approved prescription drug products, reference-listed drugs, therapeutic-equivalence information, and certain patent and exclusivity data.[1] Desipramine hydrochloride tablets are generally evaluated as conventional multisource immediate-release products.

A commercial diligence review should confirm:

1. The current reference-listed drug.
2. Approved tablet strengths.
3. Therapeutic-equivalence codes for marketed generics.
4. Any current patent listings.
5. Whether the reference product is actively marketed.
6. Whether a proposed oral liquid or alternate dosage form has an appropriate reference product.

An ANDA for a conventional tablet typically requires a demonstration of pharmaceutical equivalence and bioequivalence. A new oral liquid, orally disintegrating tablet, or modified-release product may require a different regulatory strategy, including a 505(b)(2) application if the dosage form differs materially from the listed drug.[4]

Are Paragraph IV challenges relevant to desipramine hydrochloride?

Paragraph IV litigation is unlikely to be a material issue for standard desipramine hydrochloride tablets because the original product patents are long expired and the product is already genericized.

Paragraph IV activity could become relevant if a company develops:

• A patented modified-release formulation.
• A novel oral liquid with a protected taste-masking system.
• A combination product.
• A patented method of use with a commercially meaningful indication.
• A formulation with a listed patent owned by a current 505(b)(2) sponsor.

For a conventional generic tablet, litigation risk is more likely to arise from manufacturing, quality, labeling, or supply disputes than from patent infringement.

What are the strongest formulation opportunities?

FDA-approved oral solution or suspension

An oral liquid could serve patients who cannot swallow tablets and enable more precise titration at low doses. Desipramine hydrochloride’s salt form may support aqueous formulation, but the sponsor would need to address:

• Chemical stability in solution.
• pH-dependent degradation.
• Preservative efficacy.
• Container-closure compatibility.
• Sedimentation or redispersibility if a suspension is used.
• Palatability and taste masking.
• Dosing-device accuracy.
• In-use stability after opening.

An oral liquid is the clearest differentiated product opportunity, but it carries higher development and regulatory cost than a tablet.

Orally disintegrating tablet

An orally disintegrating tablet could target dysphagia, psychiatric-care settings, and supervised administration. The main development issues are bitter taste, tablet friability, moisture sensitivity, and dose uniformity at the 10 mg and 25 mg strengths.

A rapidly disintegrating tablet without strong taste masking may have poor patient acceptance. A protected taste-masking system could create a stronger commercial position, although it would raise development cost.

Modified-release formulation

A once-daily modified-release product could improve adherence and reduce peak-related adverse effects. The opportunity is technically more complex because desipramine has clinically important pharmacokinetic and safety considerations. A modified-release product would require comparative pharmacokinetic work and careful dose-conversion analysis.

This strategy has greater potential for formulation patent protection than a standard tablet, but the addressable market may be too small to support development unless a partner has an existing controlled-release platform.

Sprinkle or enteric-coated product

Sprinkle capsules or enteric-coated systems may address swallowing difficulties or gastrointestinal tolerability. Their value is uncertain because desipramine is already available in low-strength tablets and the product has limited current prescribing volume.

How strong is the desipramine hydrochloride patent estate?

The patent estate is weak for conventional products and potentially moderate for a genuinely differentiated dosage form.

Product concept	Patent strength	Regulatory complexity	Commercial attractiveness
Conventional immediate-release tablet	Low	Low	Low to moderate
Lactose-free tablet	Low	Low to moderate	Moderate
Dye-free tablet	Low	Low	Low
Oral solution	Moderate if novel	Moderate to high	Moderate
Orally disintegrating tablet	Moderate if taste-masked	Moderate	Moderate
Modified-release tablet	Moderate to high	High	Uncertain
Combination product	Potentially high	High	Indication-dependent

The most defensible IP would likely cover a specific formulation, release profile, taste-masking system, or manufacturing process. The patent position would still need to be evaluated against obviousness risks and the limited size of the commercial market.

Which companies are challenging desipramine hydrochloride?

Desipramine hydrochloride is a mature generic product, so competitive pressure is more likely to come from multiple ANDA holders and contract manufacturers than from a named patent challenger.

Relevant competitive groups include:

• Established generic manufacturers with legacy tablet portfolios.
• Contract development and manufacturing organizations.
• Specialty generic companies supplying low-volume psychiatric products.
• Compounding pharmacies offering oral liquids where no commercial liquid is available.
• Manufacturers pursuing alternate dosage forms through 505(b)(2) applications.

The principal competitive advantage is reliable supply. A company that maintains uninterrupted availability across all six historical strengths may gain pharmacy and institutional business even without formulation exclusivity.

What generic launch risks exist?

A generic launch faces several risks despite the absence of major patent barriers.

Market-size risk

Desipramine prescriptions are materially smaller than those of modern antidepressants. Low annual volume can make validation, stability testing, packaging, and pharmacovigilance disproportionately expensive.

Strength coverage risk

A sponsor that launches only high strengths may miss patients who require low-dose titration. A full strength portfolio improves substitution potential but increases inventory and stability costs.

Supply-chain risk

The active ingredient is a low-volume material. Supplier concentration, minimum order quantities, and API discontinuation can create stockouts. The manufacturer should qualify more than one API source where feasible.

Bioequivalence risk

Differences in particle size, polymorphic form, granulation, lubricant concentration, and disintegration behavior can affect dissolution and bioequivalence. Low-dose strengths require particular attention to blend uniformity.

Labeling and safety risk

Desipramine carries class-related tricyclic antidepressant risks, including cardiovascular and central nervous system effects. Labeling must remain aligned with the FDA-approved reference product.[2]

How does desipramine compare with competing antidepressants?

Desipramine is commercially disadvantaged against generic SSRIs and SNRIs because those products have broader first-line use and larger prescribing volumes.

Product class	Typical commercial position versus desipramine
SSRIs	Larger market, broader use, lower perceived safety burden
SNRIs	Larger market, strong use in depression and pain
Other tricyclics	More established in pain or sleep-related prescribing
Desipramine	Narrower, specialist-driven demand and legacy use
Compounded antidepressant liquids	Potential substitute for dysphagia and titration patients

Desipramine can still occupy a profitable niche when supplied as a dependable, low-cost product with all major strengths and an excipient profile that supports institutional procurement.

What licensing deals could support a desipramine product?

A licensing strategy would make the most sense for an alternate dosage form rather than a standard tablet. Potential partners include:

• A liquid-formulation company with taste-masking technology.
• A specialty generic company with 505(b)(2) experience.
• A CDMO with low-dose content-uniformity and oral-liquid capabilities.
• A hospital-focused supplier seeking shortage-resistant psychiatric products.
• A packaging company offering unit-dose adherence systems.

A conventional tablet license is less attractive because the product lacks meaningful exclusivity and can face price competition from established generic suppliers.

Key Takeaways

• Desipramine hydrochloride is a mature generic drug with weak patent protection for conventional tablets.
• The commercial opportunity is based on supply reliability, strength coverage, and manufacturing efficiency.
• Lactose-free, dye-free, and small-tablet formulations offer modest differentiation but limited patent value.
• Oral liquids and orally disintegrating tablets provide the clearest formulation opportunities.
• Modified-release products offer greater IP potential but carry substantial clinical, regulatory, and market-size risk.
• Low-dose tablet strengths require strong controls for blend uniformity, segregation, friability, and dissolution.
• Paragraph IV litigation is unlikely to affect a conventional tablet launch.
• An excipient strategy should prioritize quality, stability, patient usability, and cost rather than novelty alone.

FAQs About Desipramine Hydrochloride Excipients and Commercialization

Can desipramine hydrochloride be formulated without lactose?

Yes. Microcrystalline cellulose, dibasic calcium phosphate, pregelatinized starch, or other suitable diluents can replace lactose, subject to formulation development and FDA requirements.

Is a desipramine hydrochloride oral liquid commercially available?

Commercial availability depends on the market and manufacturer. Oral liquids may be prepared extemporaneously, but an FDA-approved liquid would require its own regulatory support, stability program, labeling, and manufacturing controls.

Does desipramine hydrochloride have biosimilar competition?

No. Desipramine hydrochloride is a small-molecule drug, so competition occurs through generic drug pathways rather than biosimilar approval.

Can a lactose-free desipramine tablet receive patent protection?

A lactose-free formulation could be patentable only if it contains a novel, non-obvious technical solution. Lactose replacement alone would generally provide weak patent protection.

Which desipramine strength has the greatest formulation opportunity?

The 10 mg and 25 mg strengths offer the greatest opportunity for tablet-size reduction, improved dose titration, and alternate dosage forms. They also present the greatest content-uniformity and blend-segregation challenges.

References

1. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

2. U.S. National Library of Medicine. (n.d.). DailyMed: Desipramine hydrochloride tablet labeling. https://dailymed.nlm.nih.gov/dailymed/

3. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/

4. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). https://www.fda.gov/drugs/development-resources/applications-covered-section-505b2

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.